1-9 of 9
Pedro P. López-Casas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial

Francesca Sarno, Jair Tenorio, Sofia Perea, Laura Medina, Roberto Pazo-Cid, Ignacio Juez, Rocio Garcia-Carbonero, Jaime Feliu, Carmen Guillen-Ponce, Pedro P. Lopez-Casas, Carmen Guerra, Yolanda Duran, Jose Francisco López-Acosta, Carolina Alonso, Estrella Esquivel, Ana Dopazo, Dipikaa Akshinthala, Senthil K. Muthuswamy, Pablo Lapunzina, Bruno Bockorny, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-23-4026
Published: 14 November 2024
View article titled, A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial
Open the PDF for A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial in another window
Includes: Supplementary data
Journal Articles

OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models

Myriam Fabre, Cristina Ferrer, Saioa Domínguez-Hormaetxe, Bruno Bockorny, Laura Murias, Oliver Seifert, Stephan A. Eisler, Roland E. Kontermann, Klaus Pfizenmaier, So Young Lee, María dM. Vivanco, Pedro P. López-Casas, Sofia Perea, Muhammad Abbas, Wolfgang Richter, Laureano Simon, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3420–3430.
https://doi.org/10.1158/1078-0432.CCR-19-2238
Published: 01 July 2020
View article titled, OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models
Open the PDF for OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Personalized RNA Medicine for Pancreatic Cancer

Maud-Emmanuelle Gilles, Liangliang Hao, Ling Huang, Rajesha Rupaimoole, Pedro P. Lopez-Casas, Emilia Pulver, Jong Cheol Jeong, Senthil K. Muthuswamy, Manuel Hidalgo, Sangeeta N. Bhatia, Frank J. Slack
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (7): 1734–1747.
https://doi.org/10.1158/1078-0432.CCR-17-2733
Published: 02 April 2018
View article titled, Personalized RNA Medicine for Pancreatic Cancer
Open the PDF for Personalized RNA Medicine for Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P. Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I. Chudova, Richard B. Lanman, Peter Olson, Lyudmilla Bazhenova, Sandip Pravin Patel, Carrie Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, James G. Christensen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6661–6672.
https://doi.org/10.1158/1078-0432.CCR-17-1192
Published: 31 October 2017
View article titled, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <em>MET</em> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Open the PDF for Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <em>MET</em> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract B44: When murine tumors are thought to be human: A drawback of patient derived xenografts.

Camino Menéndez, Beatriz Salvador, Manuel Muñoz, Natalia Baños, Francesca Sarno, Pedro P López-Casas, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B44.
https://doi.org/10.1158/1557-3265.PDX16-B44
Published: 15 August 2016
View article titled, Abstract B44: When murine tumors are thought to be human: A drawback of patient derived xenografts.
Journal Articles

Abstract B42: Patient-derived metastatic models of pancreatic cancer: An in-vivo system for modeling metastasis and preclinical drug screening

Spas Dimitrov, Manuel Muñoz, Natalia Baños, Camino Menéndez, Victoria Bonilla, Yolanda Duran, Rodrigo Toledo, Francesca Sarno, Javier Perales-Patón, Fátima Al-Shahrour, Pedro P Lopez-Casas, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B42.
https://doi.org/10.1158/1557-3265.PDX16-B42
Published: 15 August 2016
View article titled, Abstract B42: Patient-derived metastatic models of pancreatic cancer: An in-vivo system for modeling metastasis and preclinical drug screening
Journal Articles

Abstract A36: Assessment of effectiveness and molecular markers of CDK4/6 inhibitor Palbociclib in Pancreatic Ductal Adenocarcinomas

Beatriz Salvador, Pedro P. López-Casas, Camino Menéndez, Natalia Baños, Francesca Sarno, Yin Min-Jean, Peter Olson, Todd VanArsdale, David J. Shields, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A36.
https://doi.org/10.1158/1557-3265.PDX16-A36
Published: 15 August 2016
View article titled, Abstract A36: Assessment of effectiveness and molecular markers of CDK4/6 inhibitor Palbociclib in Pancreatic Ductal Adenocarcinomas
Journal Articles

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B. Brachmann, Carla Heise, Daniel Pierce, Pedro P. Lopez-Casas, Camino Menendez, Josep Tabernero, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4811–4818.
https://doi.org/10.1158/1078-0432.CCR-14-3222
Published: 01 November 2015
View article titled, SPARC Expression Did Not Predict Efficacy of <em>nab</em>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Open the PDF for SPARC Expression Did Not Predict Efficacy of <em>nab</em>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial in another window
Includes: Supplementary data
Journal Articles

Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Elena Garralda, Keren Paz, Pedro P. López-Casas, Siân Jones, Amanda Katz, Lisa M. Kann, Fernando López-Rios, Francesca Sarno, Fátima Al-Shahrour, David Vasquez, Elizabeth Bruckheimer, Samuel V. Angiuoli, Antonio Calles, Luis A. Diaz, Victor E. Velculescu, Alfonso Valencia, David Sidransky, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2476–2484.
https://doi.org/10.1158/1078-0432.CCR-13-3047
Published: 30 April 2014
View article titled, Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment
Open the PDF for Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment in another window
Includes: Supplementary data